Cargando…
Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae
INTRODUCTION: Pneumococcal infections are a major cause of morbidity and mortality worldwide, whose treatment is threatened with an increase in the number of strains resistant to antibiotic therapy. GOAL: The main goal of this research was to investigate the presence of antimicrobial susceptibility/...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AVICENA, d.o.o., Sarajevo
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499292/ https://www.ncbi.nlm.nih.gov/pubmed/26236165 http://dx.doi.org/10.5455/msm.2015.27.180-184 |
_version_ | 1782380765958373376 |
---|---|
author | Karcic, Emina Aljicevic, Mufida Bektas, Sabaheta Karcic, Bekir |
author_facet | Karcic, Emina Aljicevic, Mufida Bektas, Sabaheta Karcic, Bekir |
author_sort | Karcic, Emina |
collection | PubMed |
description | INTRODUCTION: Pneumococcal infections are a major cause of morbidity and mortality worldwide, whose treatment is threatened with an increase in the number of strains resistant to antibiotic therapy. GOAL: The main goal of this research was to investigate the presence of antimicrobial susceptibility/resistance of S. pneumoniae. MATERIAL AND METHODS: Taken are swabs of the nose and nasopharynx, eye and ear. In vitro tests that were made in order to study the antimicrobial resistance of pneumococci are: disk diffusion method and E-test. RESULTS: The resistance to inhibitors of cell wall synthesis was recorded at 39.17%, protein synthesis inhibitors 19.67%, folate antagonists 47.78% and quinolone in 1.11%. S. pneumoniae has shown drug resistance to erythromycin in 45%, clindamycin in 45%, chloramphenicol–0.56%, rifampicin–6.11%, tetracycline–4.67%, penicillin-G in 4.44%, oxacillin in 73.89%, ciprofloxacin in 1.11% and trimethoprim-sulfamethoxazole in 5.34% of cases. CONCLUSION: The highest resistance pneumococcus showed to erythromycin, clindamycin and trimethoprim-sulfamethoxazole and these should be avoided in the treatment. The least resistance pneumococcus showed to tetracycline, rifampicin, chloramphenicol, penicillin-G and ciprofloxacin. |
format | Online Article Text |
id | pubmed-4499292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | AVICENA, d.o.o., Sarajevo |
record_format | MEDLINE/PubMed |
spelling | pubmed-44992922015-07-31 Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae Karcic, Emina Aljicevic, Mufida Bektas, Sabaheta Karcic, Bekir Mater Sociomed Original Paper INTRODUCTION: Pneumococcal infections are a major cause of morbidity and mortality worldwide, whose treatment is threatened with an increase in the number of strains resistant to antibiotic therapy. GOAL: The main goal of this research was to investigate the presence of antimicrobial susceptibility/resistance of S. pneumoniae. MATERIAL AND METHODS: Taken are swabs of the nose and nasopharynx, eye and ear. In vitro tests that were made in order to study the antimicrobial resistance of pneumococci are: disk diffusion method and E-test. RESULTS: The resistance to inhibitors of cell wall synthesis was recorded at 39.17%, protein synthesis inhibitors 19.67%, folate antagonists 47.78% and quinolone in 1.11%. S. pneumoniae has shown drug resistance to erythromycin in 45%, clindamycin in 45%, chloramphenicol–0.56%, rifampicin–6.11%, tetracycline–4.67%, penicillin-G in 4.44%, oxacillin in 73.89%, ciprofloxacin in 1.11% and trimethoprim-sulfamethoxazole in 5.34% of cases. CONCLUSION: The highest resistance pneumococcus showed to erythromycin, clindamycin and trimethoprim-sulfamethoxazole and these should be avoided in the treatment. The least resistance pneumococcus showed to tetracycline, rifampicin, chloramphenicol, penicillin-G and ciprofloxacin. AVICENA, d.o.o., Sarajevo 2015-06 2015-06-08 /pmc/articles/PMC4499292/ /pubmed/26236165 http://dx.doi.org/10.5455/msm.2015.27.180-184 Text en Copyright: © Emina Karcic, Mufida Aljicevic, Sabaheta Bektas, Bekir Karcic http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Karcic, Emina Aljicevic, Mufida Bektas, Sabaheta Karcic, Bekir Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae |
title | Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae |
title_full | Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae |
title_fullStr | Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae |
title_full_unstemmed | Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae |
title_short | Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae |
title_sort | antimicrobial susceptibility/resistance of streptococcus pneumoniae |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499292/ https://www.ncbi.nlm.nih.gov/pubmed/26236165 http://dx.doi.org/10.5455/msm.2015.27.180-184 |
work_keys_str_mv | AT karcicemina antimicrobialsusceptibilityresistanceofstreptococcuspneumoniae AT aljicevicmufida antimicrobialsusceptibilityresistanceofstreptococcuspneumoniae AT bektassabaheta antimicrobialsusceptibilityresistanceofstreptococcuspneumoniae AT karcicbekir antimicrobialsusceptibilityresistanceofstreptococcuspneumoniae |